Necessity of lysophosphatidic acid receptor 1 for development of arthritis

Arthritis and Rheumatism

Volumn 65, Issue 8, 2013, Pages 2037-2047

  Miyabe, Yoshishige ^a   Miyabe, Chie ^a,b   Iwai, Yoshiko ^a   Takayasu, Aiko ^a   Fukuda, Shin ^a   Yokoyama, Waka ^a   Nagai, Jun ^c   Jona, Masahiro ^d   Tokuhara, Yasunori ^d   Ohkawa, Ryunosuke ^d   Albers, Harald M ^e   Ovaa, Huib ^e   Aoki, Junken ^f   Chun, Jerold ^g   Yatomi, Yutaka ^d   Ueda, Hiroshi ^c   Miyasaka, Masayuki ^h   Miyasaka, Nobuyuki ^a   Nanki, Toshihiro ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f TOHOKU UNIVERSITY   (Japan)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

^h OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; INTERLEUKIN 17; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATORY CELL; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SPLEEN CELL; SYNOVIUM; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

AGED; ANIMALS; ANTIGENS, CD11B; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL TRANSPLANTATION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; OSTEOARTHRITIS; OSTEOCLASTS; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION; SPLEEN; SYNOVIAL MEMBRANE; TH17 CELLS;

EID: 84881342831     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37991     Document Type: Article

References (41)

1. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR,. Macrophages in rheumatoid arthritis. Arthritis Res 2000; 2: 189-202.
2. Ritchlin C,. Fibroblast biology: effector signals released by the synovial fibroblast in arthritis. Arthritis Res 2000; 2: 356-60.
3. Tanaka Y,. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 2012; 24: 319-26.
4. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T,. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009; 19: 478-87.
5. Harigai M, Koike R, Miyasaka N, for the Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007; 357: 1874-6.
6. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 2011; 38: 1258-64.
7. Schleicher SM, Thotala DK, Linkous AG, Hu R, Leahy KM, Yazlovitskaya EM, et al. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS One 2011; 6: e22182.
8. Xu X, Prestwich GD,. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 2010; 116: 1739-50.
9. Houben AJ, Moolenaar WH,. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev 2011; 30: 557-65.
10. Aoki J,. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 2004; 15: 477-89.
11. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002; 158: 227-33.
12. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases [published erratum appears in Cancer Cell 2009;16:172]. Cancer Cell 2009; 156: 539-50.
13. Masuda A, Nakamura K, Izutsu K, Igarashi K, Ohkawa R, Jona M, et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol 2008; 143: 60-70.
14. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14: 45-54.
15. Kehlen A, Lauterbach R, Santos AN, Thiele K, Kabisch U, Weber E, et al. IL-1β- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol 2001; 123: 147-54.
16. Zhao C, Fernandes MJ, Prestwich GD, Turgeon M, Di Battista J, Clair T, et al. Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis? Mol Pharmacol 2008; 73: 587-600.
17. Nochi H, Tomura H, Tobo M, Tanaka N, Sato K, Shinozaki T, et al. Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by SF of patients with rheumatoid arthritis in fibroblast-like synovial cells. J Immunol 2008; 181: 5111-9.
18. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 2012; 209: 925-33.
19. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006; 281: 25822-30.
20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
21. Nakamura K, Takeuchi T, Ohkawa R, Okubo S, Yokota H, Tozuka M, et al. Serum lysophospholipase D/autotaxin may be a new nutritional assessment marker: study on prostate cancer patients. Ann Clin Biochem 2007; 44: 549-56.
22. Nakamura K, Igarashi K, Ide K, Ohkawa R, Okubo S, Yokota H, et al. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin Chim Acta 2008; 388: 51-8.
23. Watanabe K, Penfold ME, Matsuda A, Ohyanagi N, Kaneko K, Miyabe Y, et al. Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum 2010; 62: 3211-20.
24. A1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A 2000; 97: 13384-9.
25. Inglis JJ, Simelyte E, McCann FE, Criado G, Williams RO,. Protocol for the induction of arthritis in C57BL/6 mice. Nat Protoc 2008; 3: 612-8.
26. Sato A, Watanabe K, Kaneko K, Murakami Y, Ishido M, Miyasaka N, et al. The effect of synthetic retinoid, Am80, on T helper cell development and antibody production in murine collagen-induced arthritis. Mod Rheumatol 2010; 20: 244-51.
27. Tanaka M, Nakade S, Takaoka Y, inventors; Ono Pharmaceutic, assignee. Compounds having lysophosphatidic acid receptor antagonism and uses thereof. Japan full patent application (WO 2005/058790) filed 2004 December 17; published 2005 June 30.
28. Ishii S, Noguchi K, Yanagida K,. Non-Edg family lysophosphatidic acid (LPA) receptors. Prostaglandins Other Lipid Mediat 2009; 89: 57-65.
29. Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol 2004; 173: 7010-6.
30. H17 development by cooperating with ROR nuclear receptors. Nature 2010; 464: 1381-5.
31. Nishikawa K, Nakashima T, Hayashi M, Fukunaga T, Kato S, Kodama T, et al. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci U S A 2010; 107: 3117-22.
32. + Th cells that cause autoimmune arthritis. J Exp Med 2007; 204: 41-7.
33. Nakae S, Nambu A, Sudo K, Iwakura Y,. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171: 6173-7.
34. Fotopoulou S, Oikonomou N, Grigorieva E, Nikitopoulou I, Paparountas T, Thanassopoulou A, et al. ATX expression and LPA signalling are vital for the development of the nervous system. Dev Biol 2010; 339: 451-64.
35. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR,. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007; 6: 169-75.
36. Afzali B, Lombardi G, Lechler RI, Lord GM,. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46.
37. Maeda S, Hayami Y, Naniwa T, Ueda R,. The Th17/IL-23 axis and natural immunity in psoriatic arthritis. Int J Rheumatol 2012; 2012: 539683.
38. Hot A, Zrioual S, Toh ML, Lenief V, Miossec P,. IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 2011; 70: 341-8.
39. David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 2010; 5: e9741.
40. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O,. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 2006; 103: 9643-8.
41. Yang AH, Ishii I, Chun J,. In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. Biochim Biophys Acta 2002; 1582: 197-203.